JAK Signaling in Depression and Cognition in Male Football Players
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age30-55
SponsorEmory University
About this trial
This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation.
Eligibility criteria
Qualifiers
willing and able to give written informed consent
males
playing tackle football for at least 11 years
30-55 years of age
Disqualifiers
current or history of past autoimmune disorder
history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection
history of any type of cancer requiring treatment with more than minor surgery
unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing)
Trial design
Treatments tested in this trial
- Baricitinib
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov